Brussels, Belgium and Tokyo, Japan - June 10, 2008 at 7:00 am CEST - UCB and Otsuka Pharmaceuticals Co., Ltd. announced today that the companies have signed collaboration agreements related to UCB’s two important products in Japan. UCB and Otsuka will co-promote the anti-epileptic drug (AED), Keppra® (levetiracetam) for the adjunctive treatment of partial onset seizures and the anti-TNF alpha drug, Cimzia® (certolizumab pegol) for the treatment of Crohn’s Disease. UCB and Otsuka will also co-develop and co-promote Keppra® and Cimzia® in other indications. UCB will join Otsuka in co-promoting the anti-platelet agent Pletaal® (cilostazol) to selected accounts for a limited period.
